RAD 101 Phase 2b Interim Data Shows 90% Achievement of Primary Endpoint in Brain Metastases Trial

summarizeSummary

Radiopharm Theranostics announced positive second interim data from its Phase 2b trial of RAD 101, with 90% of patients achieving the primary endpoint in diagnosing brain metastases.

check_boxKey Events

• Strong Phase 2b Interim Results

  The second interim analysis of the RAD 101 Phase 2b clinical imaging trial showed that 90% (18/20) of patients achieved concordance between PET imaging and MRI, meeting the primary endpoint.

• Encouraging Secondary Objective Trends

  Initial data from the first five patients with six-month follow-up and/or biopsy showed a positive trend for sensitivity and specificity, key measures for diagnostic test performance.

• Advancing Towards Pivotal Trial

  The company expects final data from the full 30-patient study by June, which will guide its path toward a pivotal trial for RAD 101.

• FDA Fast Track Designation

  RAD 101 previously received U.S. FDA Fast Track Designation for distinguishing between recurrent disease and treatment effect of brain metastases.

auto_awesomeAnalysis

Radiopharm Theranostics has reported strong second interim results from its Phase 2b clinical imaging trial for RAD 101, an agent for diagnosing brain metastases. Achieving 90% concordance with MRI imaging for the primary endpoint is a significant positive signal, indicating the drug's potential efficacy. The encouraging trends in sensitivity and specificity from early follow-up data further support its diagnostic utility. This positive data, coupled with existing FDA Fast Track Designation, significantly de-risks the asset and paves the way for a pivotal trial, which is crucial for a clinical-stage biopharmaceutical company of this size. Investors should monitor the final data readout by June and subsequent plans for a pivotal trial.